Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Metastatic
Would you consider adding a CDK 4/6 inhibitor to Elacestrant after progression on AI with presence of +ESR1 mutation?
Related Questions
Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?
What is your approach to treatment in hormone receptor positive, HER2 negative (0 IHC) metastatic breast cancer with ERBB2 gene amplification after progression on AI and fulvestrant CDK4/6i with visceral crisis?
Do you recommend the use of elacestrant after prior fulvestrant in metastatic hormone positive breast cancer?
How long would you continue trastuzumab and pertuzumab in a patient with ER+ HER2+ breast cancer with initially osseous involvement treated with ACT-HP and is now in CR by PET for >2 years?
How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?
Is there a role of adding hormonal therapy to fam-trastuzumab deruxtecan in patients with metastatic ER/PR+ HER2 low breast cancer after progressing on aromatase inhibitor and CDK4/6i?
In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?
What is your preferred first line therapy for metastatic HR+ inflammatory breast cancer?
Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?
What disease characteristics will guide your choice of alpelisib plus fulvestrant (per SOLAR-1) versus capivasertib plus fulvestrant (per CAPItello-291) in Pik3ca mutated advanced ER+/HER2- breast cancer after progression on 1L ET regimen, given both are now approved in this population?
